Results 191 to 200 of about 10,402 (207)

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Annals of Oncology, 2008
E Bayever, R B Cohen, R J Schilder
exaly  

Polyethylenglykol-umhülltes (pegyliertes) liposomales Doxorubicin

Drugs, 2012
Alberto A Gabizon
exaly  

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis

European Journal of Cancer, 2009
Anastasia Constantinidou, Robin L Jones, Ian Judson   +2 more
exaly  

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

European Journal of Cancer, 2012
Bradley J Monk, Stanley B Kaye, Carolyn N Krasner   +2 more
exaly  

Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

Human and Experimental Toxicology, 1999
Mary S Newman, Alan Forrest, Peter K Working   +2 more
exaly  

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin

Cancer, 2001
Tamar Safra, Susan Groshen, Susan Jeffers   +2 more
exaly  

Pharmacokinetics of Pegylated Liposomal Doxorubicin

Clinical Pharmacokinetics, 2012
Alberto Gabizon, Hilary Shmeeda, Yechezkel Barenholz   +2 more
exaly  

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Annals of Oncology, 2012
Laurence Gladieff, Annamaria Ferrero, G De Rauglaudre   +2 more
exaly  

Pegylated Liposomal Doxorubicin

Drugs, 2012
Sean T Duggan, Duggan Sean T
exaly  

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

Gynecologic Oncology, 2004
exaly